Trials / Completed
CompletedNCT03034174
Pharmacokinetics of High-dose Tigecycline in Critically Ill Patients
Pharmacokinetics of High-dose Tigecycline in Critically Ill Patients: an Observational, Prospective Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 37 (actual)
- Sponsor
- Medical University of Lublin · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to describe the pharmacokinetics of tigecycline in critically ill patients receiving continuous venovenous haemodialysis (CVVHD) and to evaluate the frequency of pharmacokinetic/pharmacodynamic target attainment with high dosing strategy (200 mg loading dose and 100 mg/12h).
Detailed description
This is a prospective observational study performed on critically ill patients. Inclusion criteria are: severe sepsis on admission requiring broad-spectrum antibiotics. Both medical and surgical patients will be included. Any type of infections will be included (pulmonary, abdominal, urinary tract, etc.) Antibiotics regimen includes: tigecycline (200 mg every 12 hours intravenously), meropenem (2 grams every 8 hours intravenously). Blood samples (3 mL) will be collected 2, 4, 8 and 12 hours after each dose of tigecycline for 3 consecutive days. The standard arterial canula will be used to obtain samples. In each case CVVHD will be started and continued for at least 3 days' period. 30 minutes after a collection each sample will be centrifuged for 10 minutes at 3,000 rpms. Subsequently, supernatant will be collected and frozen. Serum tigecycline concentration will be measured with high performance liquid chromatography. Each patient's hemodynamics parameters will be recorded with the use of transpulmonary thermodilution technique (PICCO). Other therapies i.e.: ventilatory support, sedation, an antifungal agent will be given as required.
Conditions
Timeline
- Start date
- 2017-01-15
- Primary completion
- 2017-12-15
- Completion
- 2018-10-10
- First posted
- 2017-01-27
- Last updated
- 2023-11-24
Locations
1 site across 1 country: Poland
Source: ClinicalTrials.gov record NCT03034174. Inclusion in this directory is not an endorsement.